Imagine comparing two packages: a pharmacy-dispensed medicine and a vial marked “semaglutide — research use only.” Both display a familiar compound name. One may also advertise a high purity percentage. It is tempting to treat the difference as packaging, price or paperwork.
The useful question is what evidence belongs to each finished product. Even the container is a poor shortcut: the Zepbound label includes approved vial presentations as well as pens.[3] A vial can contain a legitimate prescription medicine. A research label, however, cannot turn a laboratory material into one.
What genuine medicines have established
Semaglutide and tirzepatide are active ingredients in FDA-approved medicines with specific indications.[1][2][3] Semaglutide activates the GLP-1 receptor; tirzepatide activates both GIP and GLP-1 receptors.[2][3] These receptor descriptions identify how the drugs act, but approval attaches to particular products and uses, rather than every material bearing the compound's name.
Wegovy's label includes long-term weight reduction in specified populations and reduction of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.[2] The injection also has an accelerated-approval indication for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced liver fibrosis.[2] That indication rests on improvement in MASH and fibrosis; continued approval may depend on confirmation of clinical benefit.[2] The qualification matters as much as the indication.
Zepbound is indicated for long-term weight reduction in adults with obesity, or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity.[3] Both labels describe these uses alongside dietary and physical-activity measures.[2][3] These are meaningful therapeutic uses. Recognizing problems with unapproved lookalikes should not erase the benefits of appropriately prescribed medicines or portray the underlying compounds as inherently illegitimate.
Known risks are part of the evidence
Approval does not mean an absence of adverse effects. Both labels list nausea, diarrhea, vomiting, constipation and abdominal pain among common reactions.[2][3] They also describe more serious concerns, including severe gastrointestinal reactions, acute pancreatitis, gallbladder disease and kidney injury associated with volume depletion.[2][3] These are reasons for clinical assessment and monitoring, rather than a prediction that every patient will experience them.
The thyroid warning needs especially careful reading. Wegovy's label reports thyroid C-cell tumors in rodents; Zepbound's specifies rats.[2][3] Both state that it is unknown whether the medicine causes these tumors, including medullary thyroid carcinoma, in humans because the human relevance of the animal findings has not been determined.[2][3] They contraindicate use in people with a personal or family history of that carcinoma or multiple endocrine neoplasia syndrome type 2.[2][3]
It would misrepresent these documents to describe the warning as proof of human thyroid cancer. It would also misrepresent them to dismiss the animal findings. The labels preserve both the warning and its uncertainty, allowing a clinician to consider a defined treatment against a particular patient's circumstances.
Compounding answers a different question
A compounded preparation is a separate category. FDA says compounding may be appropriate when a patient's medical need cannot be met by an approved drug or when that drug is not commercially available.[1] Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness or quality before marketing.[1] That distinction leaves room for legitimate compounding without treating it as interchangeable with either an approved product or a research vial.
FDA has received reports of errors involving compounded injectable semaglutide, including adverse events requiring hospitalization, and complaints about inadequate refrigeration during shipping.[1] It has also identified falsely labeled products bearing the names of nonexistent pharmacies or pharmacies that did not make them.[1] These are documented concerns, not findings about every compounded preparation.
Identity can differ too. FDA describes semaglutide sodium and semaglutide acetate as different active ingredients from the one used in approved drugs; it lacks information establishing the same chemical and pharmacologic properties and identifies no lawful basis for their use in compounding.[1] A near-identical name therefore cannot settle equivalence. Equally, adverse-event reports alone cannot establish an incidence rate or prove that a particular product caused an event; FDA explicitly notes uncertainty about causation.[1]
Why purity cannot carry the whole argument
Consider a hypothetical, authentic chemical-purity report. Its result must be interpreted within the method and sample it describes. It does not, by itself, answer every question needed to establish a medicine's quality, performance or clinical suitability. The following table separates those questions; it is an explanation of evidence requirements, not a test result for any vendor.
| Question | What must be established beyond a purity number |
|---|---|
| Identity | The actual active ingredient, including whether a different salt form is present; FDA documents this distinction for semaglutide.[1] |
| Formulation | The finished composition and presentation; the approved labels specify particular pharmaceutical forms.[2][3] |
| Manufacturing and storage | Appropriate production controls and a reliable supply history; FDA identifies both manufacturing and shipping concerns.[1] |
| Microbiological quality | Evidence addressing microorganisms and toxins; FDA highlights the consequences of bypassing bodily defenses with injectable products.[4] |
| Exposure | Evidence about how the particular preparation behaves in the body, rather than assuming similar names establish similar pharmacologic properties.[1] |
| Clinical use | Evidence supporting the relevant product, indication and population; approved uses have explicit boundaries.[2][3] |
Reconstitution does not supply those missing answers. Preparing a research material for an experiment is not a substitute for establishing a pharmaceutical formulation. The conclusion is narrower than “every research vial is contaminated”: a purity claim alone cannot establish medicinal equivalence, sterility or suitability for self-administration.
What a research label can—and cannot—say
FDA describes products sold directly to consumers for human use while falsely labeled “for research purposes” or “not for human consumption,” including semaglutide and tirzepatide products of unknown quality.[1] In a separate June 2026 warning letter concerning other compounds, FDA explained that human-use claims could establish drug intent despite research-only disclaimers.[4] That letter supports the regulatory distinction; it does not establish contamination in any semaglutide vial.
Research materials should not be consumed or self-administered. For treatment, FDA directs patients toward a doctor's prescription and a state-licensed pharmacy.[1] A scientifically useful compound, a legitimate research reagent and an approved medicine can share a name while carrying very different evidence. Understanding that difference protects the value of research and the value of properly evaluated treatment.
Source scope: This article interprets FDA guidance and retrieved prescribing-information excerpts available for the October 22, 2026 editorial review. It reports no Chudik experiments or product-specific testing.